We came across a bullish thesis on Cencora, Inc. (COR) on Substack by Hidden Market Gems. In this article, we will summarize ...

Since April 2020, the S&P 500 has delivered a total return of 101%. But one standout stock has more than doubled the market - over the past five years, Cencora has surged 231% to $285.36 per share.

AmerisourceBergen’s move into the digital health area is part of a revamp of the business, which will be renamed Cencora later this year to reflect a change in business strategy, with ...

$60,000 of CENCORA INC. lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "IRA implementation. Drug Shortages ...

Morgan Stanley analyst Erin Wright raised the firm’s price target on Cencora (COR) to $288 from $263 and keeps an Equal Weight rating on the shares. While policy will be “front and center ...

Citi analyst Daniel Grosslight maintained a Buy rating on Cencora (COR – Research Report) today and set a price target of $330.00. The company’s shares closed yesterday at $284.44. Discover ...

Formerly known as AmerisourceBergen until its 2023 rebranding, Cencora (NYSE:COR) is a global pharmaceutical distribution company that connects manufacturers with healthcare providers while ...

Pharma distributor AmerisourceBergen is working on a platform to make access to digital therapeutics (DTx) easier in the US by providing a unified system for ordering, dispensing and fulfilment.

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 8.3% over the past month. The stock hit a new 52-week high of $271.86 in the previous session.

Cencora COR has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...